Download PDF
CC BY 4.0 · Glob Med Genet 2021; 08(01): 032-037
DOI: 10.1055/s-0041-1724106
Original Article

Lack of Molecular Mimicry between Nonhuman Primates and Infectious Pathogens: The Possible Genetic Bases

Darja Kanduc 
1   Department of Biosciences, Biotechnologies, and Biopharmaceutics, University of Bari, Bari, Italy
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Recently, it was found that proteomes from poliovirus, measles virus, dengue virus, and severe acute respiratory syndrome-related Coronavirus 2 (SARS-CoV-2) have high molecular mimicry at the heptapeptide level with the human proteome, while heptapeptide commonality is minimal or absent with proteomes from nonhuman primates, that is, gorilla, chimpanzee, and rhesus macaque. To acquire more data on the issue, analyses here have been expanded to Ebola virus, Francisella tularensis, human immunodeficiency virus-1 (HIV-1), Toxoplasma gondii, Variola virus, and Yersinia pestis. Results confirm that heptapeptide overlap is high between pathogens and Homo sapiens, but not between pathogens and primates. Data are discussed in light of the possible genetic bases that differently model primate phenomes, thus possibly underlying the zero/low level of molecular mimicry between infectious agents and primates. Notably, this study might help address preclinical vaccine tests that currently utilize primates as animal models, since autoimmune cross-reactions and the consequent adverse events cannot occur in absentia of shared sequences.

Keywords

infectious agents - peptide sharing - molecular mimicry - cross-reactivity - autoimmunity - nonhuman primates - rhesus macaque - vaccines - preclinical test

Supplementary Material



Publication History

Article published online:
19 February 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Natale C, Giannini T, Lucchese A, Kanduc D. Computer-assisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences. Immunol Cell Biol 2000; 78 (06) 580-585
    CrossrefPubMedGoogle Scholar
  • 2 Kanduc D, Stufano A, Lucchese G, Kusalik A. Massive peptide sharing between viral and human proteomes. Peptides 2008; 29 (10) 1755-1766
    CrossrefPubMedGoogle Scholar
  • 3 Trost B, Lucchese G, Stufano A, Bickis M, Kusalik A, Kanduc D. No human protein is exempt from bacterial motifs, not even one. Self Nonself 2010; 1 (04) 328-334
    CrossrefPubMedGoogle Scholar
  • 4 Lucchese G, Kanduc D. Zika virus and autoimmunity: from microcephaly to Guillain-Barré syndrome, and beyond. Autoimmun Rev 2016; 15 (08) 801-808
    CrossrefPubMedGoogle Scholar
  • 5 Kanduc D, Shoenfeld Y. Inter-pathogen peptide sharing and the original antigenic sin: Solving a paradox. Open Immunol J 2018; 8: 11-27
    CrossrefGoogle Scholar
  • 6 Lucchese G. Confronting JC virus and Homo sapiens biological signatures. Front Biosci 2013; 18: 716-724
    CrossrefPubMedGoogle Scholar
  • 7 Kanduc D. HCV: Written in our DNA. Self Nonself 2011; 2 (02) 108-113
    CrossrefPubMedGoogle Scholar
  • 8 Kanduc D. Describing the hexapeptide identity platform between the influenza A H5N1 and Homo sapiens proteomes. Biologics 2010; 4: 245-261
    PubMedGoogle Scholar
  • 9 Lucchese A, Serpico R, Crincoli V, Shoenfeld Y, Kanduc D. Sequence uniqueness as a molecular signature of HIV-1-derived B-cell epitopes. Int J Immunopathol Pharmacol 2009; 22 (03) 639-646
    CrossrefPubMedGoogle Scholar
  • 10 Kanduc D. From anti-SARS-CoV-2 immune responses to COVID-19 via molecular mimicry. Antibodies (Basel) 2020; 9 (03) E33
    CrossrefPubMedGoogle Scholar
  • 11 Kanduc D. Peptide cross-reactivity: the original sin of vaccines. Front Biosci (Schol Ed) 2012; 4: 1393-1401
    CrossrefPubMedGoogle Scholar
  • 12 Kanduc D. From influenza infection to anti-ADAMTS13 autoantibodies via cross-reactivity. Infect Int 2019; 7: 113-120
    CrossrefGoogle Scholar
  • 13 Kanduc D. Describing the potential crossreactome between mumps virus and spermatogenesis-associated proteins. Endocr Metab Immune Disord Drug Targets 2014; 14 (03) 218-225
    CrossrefPubMedGoogle Scholar
  • 14 Lucchese G, Capone G, Kanduc D. Peptide sharing between influenza A H1N1 hemagglutinin and human axon guidance proteins. Schizophr Bull 2014; 40 (02) 362-375
    CrossrefPubMedGoogle Scholar
  • 15 Lucchese G. Understanding neuropsychiatric diseases, analyzing the peptide sharing between infectious agents and the language-associated NMDA 2A protein. Front Psychiatry 2016; 7: 60
    CrossrefPubMedGoogle Scholar
  • 16 Lucchese G. From toxoplasmosis to schizophrenia via NMDA dysfunction: peptide overlap between Toxoplasma gondii and N-Methyl-d-Aspartate Receptors as a potential mechanistic link. Front Psychiatry 2017; 8: 37
    CrossrefPubMedGoogle Scholar
  • 17 Lucchese G, Kanduc D. Single amino acid repeats connect viruses to neurodegeneration. Curr Drug Discov Technol 2014; 11 (03) 214-219
    CrossrefPubMedGoogle Scholar
  • 18 Kanduc D, Shoenfeld Y. From anti-EBV immune responses to the EBV diseasome via cross-reactivity. Glob Med Genet 2020; 7 (02) 51-63
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Kanduc D. Potential cross-reactivity between HPV16 L1 protein and sudden death-associated antigens. J Exp Ther Oncol 2011; 9 (02) 159-165
    PubMedGoogle Scholar
  • 20 Capone G, Kanduc D. Peptide sharing between Bordetella pertussis proteome and human sudden death proteins: a hypothesis for a causal link. Future Microbiol 2013; 8 (08) 1039-1048
    CrossrefPubMedGoogle Scholar
  • 21 Kanduc D, Shoenfeld Y. Human papillomavirus epitope mimicry and autoimmunity: the molecular truth of peptide sharing. Pathobiology 2019; 86 (5-6): 285-295
    CrossrefPubMedGoogle Scholar
  • 22 Kanduc D. Influenza and sudden unexpected death: the possible role of peptide cross-reactivity. Infect Int 2019; 7: 121-131
    CrossrefGoogle Scholar
  • 23 Kanduc D, Shoenfeld Y. On the molecular determinants of the SARS-CoV-2 attack. Clin Immunol 2020; 215: 108426
    CrossrefPubMedGoogle Scholar
  • 24 Kanduc D. Measles virus hemagglutinin epitopes are potential hotspots for crossreactions with immunodeficiency-related proteins. Future Microbiol 2015; 10 (04) 503-515
    CrossrefPubMedGoogle Scholar
  • 25 Kanduc D, Polito A. From viral infections to autistic neurodevelopmental disorders via cross-reactivity. J Psychiatry Brain Sci 2018; 3: 14
    Google Scholar
  • 26 Kanduc D. From hepatitis C virus immunoproteomics to rheumatology via cross-reactivity in one table. Curr Opin Rheumatol 2019; 31 (05) 488-492
    CrossrefPubMedGoogle Scholar
  • 27 Kanduc D. Immunobiology: on the inexistence of a negative selection process. Adv Stud Biol 2020; 12: 19-28
    CrossrefGoogle Scholar
  • 28 Kanduc D. Hydrophobicity and the physico-chemical basis of immunotolerance. Pathobiology 2020; 87 (04) 268-276
    CrossrefPubMedGoogle Scholar
  • 29 Kanduc D, Shoenfeld Y. Molecular mimicry between SARS-CoV-2 spike glycoprotein and mammalian proteomes: implications for the vaccine. Immunol Res 2020; 68 (05) 310-313
    CrossrefPubMedGoogle Scholar
  • 30 Kanduc D, Shoenfeld Y. Medical, genomic, and evolutionary aspects of the peptide sharing between pathogens, primates, and humans. Glob Med Genet 2020; 7 (02) 64-67
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Abee CR, Keeling ME, Mansfield K, Tardif S, Morris T. Nonhuman Primates in Biomedical Research. Vol. 2: Diseases. Academic Press, Elsevier; Oxford, UK: 2012
    Google Scholar
  • 32 Pasetti MF, Resendiz-Albor A, Ramirez K. et al. Heterologous prime-boost strategy to immunize very young infants against measles: pre-clinical studies in rhesus macaques. Clin Pharmacol Ther 2007; 82 (06) 672-685
    CrossrefPubMedGoogle Scholar
  • 33 Verstrepen BE, Oostermeijer H, Fagrouch Z. et al. Vaccine-induced protection of rhesus macaques against plasma viremia after intradermal infection with a European lineage 1 strain of West Nile virus. PLoS One 2014; 9 (11) e112568
    CrossrefPubMedGoogle Scholar
  • 34 Stephenson KE, Wegmann F, Tomaka F. et al. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22). Lancet HIV 2020; 7 (06) e410-e421
    CrossrefPubMedGoogle Scholar
  • 35 van Doremalen N, Lambe T, Spencer A. et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature 2020; 586 (7830): 578-582
    CrossrefPubMedGoogle Scholar
  • 36 Lu S, Zhao Y, Yu W. et al. Comparison of nonhuman primates identified the suitable model for COVID-19. Signal Transduct Target Ther 2020; 5 (01) 157
    CrossrefPubMedGoogle Scholar
  • 37 Sun W, Singh AK. Plague vaccine: recent progress and prospects. npjVaccines 2019; (e-pub ahead of print) DOI: 10.1038/s41541-019-0105-9.
    CrossrefPubMedGoogle Scholar
  • 38 Shedlock DJ, Silvestri G, Weiner DB. Monkeying around with HIV vaccines: using rhesus macaques to define ‘gatekeepers’ for clinical trials. Nat Rev Immunol 2009; 9 (10) 717-728
    CrossrefPubMedGoogle Scholar
  • 39 UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res 2019; 47 (D1): D506-D515
    CrossrefPubMedGoogle Scholar
  • 40 Chen C, Li Z, Huang H, Suzek BE, Wu CH. UniProt Consortium. A fast Peptide Match service for UniProt Knowledgebase. Bioinformatics 2013; 29 (21) 2808-2809
    CrossrefPubMedGoogle Scholar
  • 41 Morgat A, Lombardot T, Coudert E. et al; UniProt Consortium. Enzyme annotation in UniProtKB using Rhea. Bioinformatics 2020; 36 (06) 1896-1901
    CrossrefPubMedGoogle Scholar
  • 42 Varki A. A chimpanzee genome project is a biomedical imperative. Genome Res 2000; 10 (08) 1065-1070
    CrossrefPubMedGoogle Scholar
  • 43 Olson MV, Varki A. Sequencing the chimpanzee genome: insights into human evolution and disease. Nat Rev Genet 2003; 4 (01) 20-28
    CrossrefPubMedGoogle Scholar
  • 44 Varki A, Altheide TK. Comparing the human and chimpanzee genomes: searching for needles in a haystack. Genome Res 2005; 15 (12) 1746-1758
    CrossrefPubMedGoogle Scholar
  • 45 Lucchese G, Stufano A, Calabro M, Kanduc D. Charting the peptide crossreactome between HIV-1 and the human proteome. Front Biosci (Elite Ed) 2011; 3: 1385-1400
    Google Scholar
  • 46 Barouch DH, Tomaka FL, Wegmann F. et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet 2018; 392 (10143): 232-243
    CrossrefPubMedGoogle Scholar
  • 47 Thomas C. Roadblocks in HIV research: five questions. Nat Med 2009; 15 (08) 855-859
    CrossrefPubMedGoogle Scholar
  • 48 Cohen J. Another HIV vaccine strategy fails in large-scale study. Science 2020; (e-pub ahead of print) DOI: 10.1126/science.abb1480.
    CrossrefGoogle Scholar
  • 49 Sabin AB. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis 1985; 151 (03) 420-436
    CrossrefPubMedGoogle Scholar
  • 50 Lerner A, Jeremias P, Matthias T. The world incidence and prevalence of autoimmune diseases is increasing. Int J Celiac Dis 2015; 3: 151-155
    CrossrefGoogle Scholar
  • 51 Bond KA, Franklin LJ, Sutton B, Firestone SM. Q-Vax Q fever vaccine failures, Victoria, Australia 1994-2013. Vaccine 2017; 35 (51) 7084-7087
    CrossrefPubMedGoogle Scholar
  • 52 Breakwell L, Moturi E, Helgenberger L. et al. Measles outbreak associated with vaccine failure in adults-Federated States of Micronesia, February-August 2014. MMWR Morb Mortal Wkly Rep 2015; 64 (38) 1088-1092
    CrossrefPubMedGoogle Scholar
  • 53 Cherry JD. Epidemic pertussis and acellular pertussis vaccine failure in the 21st century. Pediatrics 2015; 135 (06) 1130-1132
    CrossrefPubMedGoogle Scholar
  • 54 Lopez-Lacort M, Collado S, Díez-Gandía A, Díez-Domingo J. Rotavirus, vaccine failure or diagnostic error?. Vaccine 2016; 34 (48) 5912-5915
    CrossrefPubMedGoogle Scholar
  • 55 Mahalingam S, Herring BL, Halstead SB. Call to action for dengue vaccine failure. Emerg Infect Dis 2013; 19 (08) 1335-1337
    CrossrefPubMedGoogle Scholar
  • 56 Moinho R, Brett A, Ferreira G, Lemos S. Pneumococcal vaccine failure: can it be a primary immunodeficiency?. BMJ Case Rep 2014; 2014: bcr2014204714
    CrossrefPubMedGoogle Scholar
  • 57 Naylor C, Lu M, Haque R. et al; PROVIDE study teams. Environmental enteropathy, oral vaccine failure and growth faltering in infants in Bangladesh. EBioMedicine 2015; 2 (11) 1759-1766
    CrossrefPubMedGoogle Scholar
  • 58 Poland GA. Influenza vaccine failure: failure to protect or failure to understand?. Expert Rev Vaccines 2018; 17 (06) 495-502
    CrossrefPubMedGoogle Scholar
  • 59 Ramsay M, Brown K. The public health implications of secondary measles vaccine failure. J Prim Health Care 2013; 5 (02) 92
    CrossrefPubMedGoogle Scholar
  • 60 Wiedermann U, Garner-Spitzer E, Wagner A. Primary vaccine failure to routine vaccines: why and what to do?. Hum Vaccin Immunother 2016; 12 (01) 239-243
    CrossrefPubMedGoogle Scholar
  • 61 Pieczenik G. Are the universes of antibodies and antigens symmetrical?. Reprod Biomed Online 2003; 6 (02) 154-156
    CrossrefPubMedGoogle Scholar
  • 62 Kanduc D. Pentapeptides as minimal functional units in cell biology and immunology. Curr Protein Pept Sci 2013; 14 (02) 111-120
    CrossrefPubMedGoogle Scholar
  • 63 Puente XS, Gutiérrez-Fernández A, Ordóñez GR, Hillier LW, López-Otín C. Comparative genomic analysis of human and chimpanzee proteases. Genomics 2005; 86 (06) 638-647
    CrossrefPubMedGoogle Scholar
  • 64 Glazko G, Veeramachaneni V, Nei M, Makałowski W. Eighty percent of proteins are different between humans and chimpanzees. Gene 2005; 346: 215-219
    CrossrefPubMedGoogle Scholar
  • 65 Sharp AJ, Locke DP, McGrath SD. et al. Segmental duplications and copy-number variation in the human genome. Am J Hum Genet 2005; 77 (01) 78-88
    CrossrefPubMedGoogle Scholar
  • 66 Hahn MW, Demuth JP, Han SG. Accelerated rate of gene gain and loss in primates. Genetics 2007; 177 (03) 1941-1949
    CrossrefPubMedGoogle Scholar
  • 67 Dumas L, Kim YH, Karimpour-Fard A. et al. Gene copy number variation spanning 60 million years of human and primate evolution. Genome Res 2007; 17 (09) 1266-1277
    CrossrefPubMedGoogle Scholar
  • 68 Marques-Bonet T, Kidd JM, Ventura M. et al. A burst of segmental duplications in the genome of the African great ape ancestor. Nature 2009; 457 (7231): 877-881
    CrossrefPubMedGoogle Scholar
  • 69 Blekhman R, Oshlack A, Gilad Y. Segmental duplications contribute to gene expression differences between humans and chimpanzees. Genetics 2009; 182 (02) 627-630
    CrossrefPubMedGoogle Scholar
  • 70 Kapopoulou A, Mathew L, Wong A, Trono D, Jensen JD. The evolution of gene expression and binding specificity of the largest transcription factor family in primates. Evolution 2016; 70 (01) 167-180
    CrossrefPubMedGoogle Scholar
  • 71 Hamilton AT, Huntley S, Tran-Gyamfi M, Baggott DM, Gordon L, Stubbs L. Evolutionary expansion and divergence in the ZNF91 subfamily of primate-specific zinc finger genes. Genome Res 2006; 16 (05) 584-594
    CrossrefPubMedGoogle Scholar
  • 72 Khaitovich P, Hellmann I, Enard W. et al. Parallel patterns of evolution in the genomes and transcriptomes of humans and chimpanzees. Science 2005; 309 (5742): 1850-1854
    CrossrefPubMedGoogle Scholar
  • 73 Enard W, Khaitovich P, Klose J. et al. Intra- and interspecific variation in primate gene expression patterns. Science 2002; 296 (5566): 340-343
    CrossrefPubMedGoogle Scholar
  • 74 Kanduc D. “Self-nonself” peptides in the design of vaccines. Curr Pharm Des 2009; 15 (28) 3283-3289
    CrossrefPubMedGoogle Scholar
  • 75 Kanduc D. The self/nonself issue: a confrontation between proteomes. Self Nonself 2010; 1 (03) 255-258
    CrossrefPubMedGoogle Scholar
  • 76 Lucchese G, Stufano A, Kanduc D. Proposing low-similarity peptide vaccines against Mycobacterium tuberculosis. J Biomed Biotechnol 2010; 2010: 832341
    CrossrefPubMedGoogle Scholar
  • 77 Angelini G, Bonamonte D, Lucchese A. et al. Preliminary data on Pemphigus vulgaris treatment by a proteomics-defined peptide: a case report. J Transl Med 2006; 4: 43
    CrossrefPubMedGoogle Scholar
  • 78 Kanduc D. Immunogenicity, immunopathogenicity, and immunotolerance in one graph. Anticancer Agents Med Chem 2015; 15 (10) 1264-1268
    CrossrefPubMedGoogle Scholar